lung
transplant
lntx
treatment
option
lung
diseas
dramat
increas
recent
infect
reject
common
complic
earli
identif
crucial
condit
present
similar
symptom
dyspnea
lower
forc
expiratori
volum
second
fever
therefor
difficult
distinguish
clinic
howev
lntx
patient
may
lack
classic
sign
infect
due
heavi
immunosuppress
reject
may
asymptomat
addit
possibl
link
infect
develop
exampl
viral
pneumonia
associ
chronic
lung
allograft
dysfunct
graft
moreov
growth
bacteria
fungi
bronchoalveolar
lavag
fluid
balf
cultur
alway
repres
infect
bacteri
fungal
colon
transplant
lung
common
infect
bacteria
pose
increas
threat
solid
organ
transplant
recipi
discrimin
infect
colon
import
start
treatment
resist
bacteria
possibl
side
effect
antimicrobi
peptid
respiratori
secret
play
import
role
first
line
defenc
lysozym
abund
airway
antimicrobi
peptid
secret
primarili
neutrophil
protein
hbp
initi
recogn
broad
antimicrobi
activ
known
multifunct
inflammatori
mediat
induc
vascular
leakag
act
chemoattract
activ
protein
store
secretori
azurophil
granul
neutrophil
rapidli
releas
upon
cell
plasma
hbp
describ
promis
biomark
sever
sepsi
septic
elev
hbp
level
also
shown
cerebrospin
fluid
bacteri
urin
urinari
tract
neither
hbp
lysozym
previous
evalu
balf
lntx
patient
studi
quantifi
two
protein
togeth
cytokin
interleukin
il
tnf
balf
collect
first
year
transplant
primari
aim
evalu
hbp
lysozym
potenti
biomark
infect
determin
abil
discrimin
infect
reject
lung
transplant
recipi
prospect
cohort
studi
conduct
univers
hospit
one
two
center
sweden
perform
lntx
adult
patient
accept
lntx
studi
period
octob
decemb
elig
inclus
patient
younger
year
age
patient
postop
site
exclud
studi
particip
follow
maximum
year
transplant
written
inform
consent
obtain
studi
patient
studi
approv
region
ethic
committe
reg
nr
perform
accord
ethic
standard
declar
helsinki
later
amend
standard
protocol
immun
suppress
includ
induct
therapi
atg
globulin
follow
tacrolimu
cyclosporin
mycophenol
mofetil
steroid
lntx
recipi
treat
cytomegaloviru
fungal
prophylaxi
month
balf
sampl
collect
routin
schedul
bronchoscopi
month
lntx
diagnost
bronchoscopi
perform
respons
clinic
symptom
minim
interv
day
allow
bal
includ
new
sampl
studi
bal
procedur
follow
standard
protocol
studi
sampl
analys
hbp
lysozym
cytokin
obtain
instal
ml
salin
pb
initi
ml
balf
discharg
studi
sampl
ml
collect
portion
ml
pb
instil
collect
balf
accord
standard
protocol
bacteri
fungal
cytolog
analys
balf
sent
univers
hospit
microbiolog
depart
bacteri
fungal
cultur
includ
microscopi
fungal
element
cultur
quantifi
three
level
spars
moder
abund
growth
pcr
mycoplasma
chlamydia
legionella
pneumocysti
herp
simplex
viru
hsv
type
parainfluenza
type
respiratori
syncyti
viru
rsv
influenza
viru
b
adenoviru
metapneumoviru
coronaviru
enteroviru
rhinoviru
bocaviru
perform
accord
standard
protocol
cytomegaloviru
cmv
blood
determin
quantit
pcr
balf
studi
sampl
centrifug
supernat
frozen
analys
transbronchi
biopsi
tbb
perform
routin
bronchoscopi
month
bronchoscopi
perform
due
deterior
graft
function
tissu
sampl
analyz
univers
hospit
depart
patholog
accord
standard
protocol
reject
defin
grade
accord
intern
societi
heart
lung
transplant
ishlt
cytolog
analysi
assess
inflammatori
cell
includ
fungal
stain
perform
univers
hospit
depart
patholog
inflamm
cytolog
tbb
report
mild
acuteabund
inflamm
likelihood
pulmonari
infect
time
balf
sampl
independ
blind
result
biomark
grade
accord
grade
score
two
infecti
diseas
clinician
asa
lip
definit
infect
adapt
ishlt
base
radiolog
b
macroscop
find
bronchial
tree
inflammatori
cell
balf
c
patient
record
assess
clinic
symptom
microbiolog
result
e
histopatholog
acut
reject
tabl
infect
grade
infect
criteria
possibl
infect
grade
fulfil
either
bronchoscopi
microbiolog
criteria
probabl
infect
grade
two
three
infect
criteria
definit
infect
grade
fulfil
criteria
definit
probabl
infect
consid
repres
infect
wherea
possibl
infect
reject
consid
repres
infect
studi
hbp
concentr
analyz
immunosorb
assay
elisa
describ
lysozym
level
quantifi
commerci
elisa
abnova
taoyuan
citi
taiwan
accord
protocol
concentr
tnf
measur
cytometr
bead
array
cba
sensit
flex
set
bd
bioscienc
san
jose
ca
use
cell
sort
fac
vers
bd
bioscienc
adjust
dilut
balf
estim
biomark
concentr
lung
epitheli
line
fluid
analyz
urea
balf
concomit
plasma
sampl
quantichrom
urea
assay
kit
bioassay
system
hayward
ca
accord
protocol
provid
manufactur
ratio
urea
plasma
urea
balf
use
coeffici
dilut
adjust
biomark
level
describ
previous
pocino
et
rank
sum
u
test
use
assess
distribut
biomark
level
differ
group
probabl
infect
infect
possibl
probabl
definit
infect
reject
characterist
roc
analys
use
assess
diagnost
power
biomark
infect
dichotom
probabledefinit
infect
compar
possibl
infect
reject
area
roc
curv
auc
compar
sensit
specif
posit
neg
predict
valu
calcul
base
level
identifi
roc
analys
maxim
sensit
specif
use
logist
regress
calcul
odd
ratio
or
infect
dichotom
definit
probabl
vs
possibl
infect
reject
biomark
use
gener
estim
equat
gee
model
account
possibl
depend
due
multipl
observ
patient
differ
biomark
first
analyz
univari
model
secondli
model
adjust
time
lntx
statist
test
confid
interv
ci
overlap
p
valu
consid
statist
signific
analys
perform
use
statas
version
window
statacorp
lp
colleg
station
tx
graphpad
prism
graphpad
softwar
la
jolla
ca
spss
version
spss
armonk
ny
softwar
total
patient
transplant
studi
period
five
patient
elig
inclus
due
anoth
center
one
patient
declin
particip
consequ
patient
includ
studi
four
particip
die
shortli
transplant
studi
sampl
collect
leav
lung
transplant
recipi
prospect
follow
studi
patient
women
men
median
age
year
underw
doubl
lung
transplant
cystic
fibrosi
common
underli
diseas
detail
patient
characterist
see
tabl
total
balf
sampl
collect
studi
period
four
sampl
exclud
three
patient
repeat
sampl
taken
day
apart
one
balf
could
separ
centrifug
left
balf
sampl
analysi
median
balf
sampl
per
patient
rang
balf
sampl
collect
routin
control
extra
bronchoscopi
extra
bal
perform
within
first
month
transplant
bronchoscopi
done
clinic
suspicion
infect
routin
control
extra
bronchoscopi
sampl
collect
ongo
treatment
antibiot
antifung
bronchoscopi
perform
week
treatment
balf
sampl
occas
radiolog
either
comput
tomographi
ct
scan
chest
radiograph
perform
adjac
bronchoscopi
sampl
analyz
bacteria
fungi
hsv
concomit
cmv
blood
evalu
virus
done
sampl
tbb
perform
bronchoscopi
routin
control
extra
control
patient
assess
infect
time
bal
describ
tabl
balf
sampl
grade
infect
balf
sampl
possibl
infect
balf
sampl
probabl
infect
balf
sampl
classifi
definit
infect
figur
among
sampl
grade
probabl
infect
patient
balf
sampl
asymptomat
time
bal
growth
bacteria
macroscop
endobronchi
sign
infect
four
patient
also
present
new
infiltr
chest
radiograph
bacteri
growth
detect
balf
sampl
pseudomona
aeruginosa
commonli
isol
bacteri
speci
follow
escherichia
coli
sampl
fungal
growth
candida
albican
aspergillu
fumigatu
domin
fungal
organ
respect
eighteen
pcr
posit
viru
coronaviru
cmv
common
agent
sampl
neg
microbiolog
result
sampl
singl
microb
balf
cultur
pcr
wherea
sampl
sampl
combin
bacteria
fungi
viru
four
patient
neg
balf
cultur
throughout
bronchoscopi
risk
infect
decreas
slightli
time
transplant
estim
logist
regress
odd
ratio
definit
probabl
infect
compar
possibl
infect
reject
ci
per
month
lntx
reject
diagnos
bronchoscopi
patient
perform
tbb
eight
sampl
grade
sampl
grade
sampl
grade
one
sampl
chronic
reject
grade
c
seven
reject
sampl
patient
concomit
possibl
probabl
infect
four
patient
repeat
tbb
show
reject
grade
also
sampl
without
concomit
infect
four
treat
steroid
respons
tbb
find
respond
clinic
fifth
patient
one
singl
tbb
reject
grade
concomit
growth
pseudomona
treat
steroid
final
one
patient
one
sampl
reject
grade
absenc
infect
receiv
treatment
reject
occur
earlier
month
transplant
calcul
sampl
reject
analyz
one
group
hbp
lysozym
test
cytokin
increas
significantli
likelihood
infect
reject
sampl
present
significantli
lower
concentr
test
biomark
compar
sampl
definit
infect
level
significantli
differ
noninfect
group
figur
sampl
collect
ongo
antibiot
andor
antifung
treatment
present
signific
differ
biomark
level
compar
nontreat
sampl
within
grade
group
auc
identif
infect
decreas
order
hbp
tnf
lysozym
p
figur
show
roc
curv
best
perform
cytokin
compar
hbp
lysozym
auc
hbp
significantli
differ
p
p
respect
hbp
valu
ngml
sensit
specif
detect
infect
posit
predict
valu
ppv
neg
predict
valu
npv
respect
perform
similar
hbp
wherea
lysozym
show
poor
sensit
specif
tabl
balf
sampl
pair
plasma
sampl
avail
allow
estim
balf
dilut
use
urea
method
adjust
dilut
factor
hbp
still
increas
significantli
infect
figur
wherea
lysozym
tnf
base
auc
valu
result
perform
best
test
cytokin
two
use
comparison
hbp
lysozym
compar
biomark
analysi
inflamm
tbb
cytolog
data
avail
sampl
hbp
lysozym
significantli
sensit
diagnos
infect
compar
grade
inflamm
auc
respect
account
possibl
bia
due
multipl
sampl
individu
adjust
time
transplant
use
gener
estim
equat
gee
model
use
gee
analys
estim
or
predict
definit
probabl
infect
compar
possibl
infect
reject
ci
hbp
ci
ci
ci
lysozym
set
prospect
studi
lung
transplant
recipi
compar
differ
biomark
predict
infect
found
hbp
best
balf
biomark
infect
sampl
patient
reject
low
level
test
biomark
concentr
rang
noninfect
sampl
neutrophil
recruit
airway
respons
infect
increas
neutrophil
number
found
balf
bacteri
neutrophil
count
analyz
studi
major
shortcom
given
hbp
lysozym
releas
activ
neutrophil
studi
demonstr
hbp
better
diagnost
marker
infect
neutrophil
count
cerebrospin
fluid
mening
urin
urinari
tract
infect
plasma
present
studi
hbp
sensit
diagnos
infect
compar
grade
inflamm
tbb
cytolog
howev
analysi
studi
requir
evalu
hbp
marker
compar
neutrophil
count
bal
similar
hbp
lysozym
cytokin
increas
likelihood
infect
mirror
increas
inflamm
properti
show
pattern
cytokin
studi
believ
play
import
role
balanc
inflammatori
respons
order
limit
host
tissu
exampl
compar
mice
mice
demonstr
effici
bacteri
clearanc
higher
mortal
increas
neutrophil
recruit
lung
respons
streptococcu
pneumonia
underscor
regulatori
role
infect
could
therefor
specul
increas
simultan
cytokin
order
avoid
excess
inflamm
would
harm
host
correct
dilut
factor
balf
use
urea
method
describ
howev
infect
urea
concentr
might
increas
balf
due
inflamm
increas
plasma
leakag
thu
caus
fals
low
biomark
level
adjust
urea
plasmab
coeffici
moreov
balf
sampl
could
urea
adjust
correspond
plasma
sampl
miss
give
test
less
power
even
hbp
show
significantli
higher
valu
infect
line
find
recent
shown
balf
potenti
marker
pneumonia
vap
strengthen
util
biomark
studi
found
signific
differ
level
reject
noninfect
biomark
contrari
result
patella
et
al
demonstr
increas
level
reject
compar
one
possibl
reason
discrep
reject
defin
differ
two
studi
identifi
reject
tbb
ensur
correct
diagnosi
test
biomark
common
indic
inflamm
contrast
reject
primarili
may
explain
none
marker
studi
elev
group
howev
distinct
difficult
infect
drive
reject
tbb
stage
also
fals
posit
presenc
infect
studi
two
patient
reject
repeat
posit
tbb
increas
likelihood
true
result
infect
report
occur
within
first
month
lntx
especi
bacteri
studi
note
tendenc
toward
decreas
risk
infect
time
transplant
howev
total
risk
infect
assess
studi
infect
occur
bronchoscopi
may
miss
cultur
sputum
locat
consid
chose
defin
infect
sampl
grade
probabl
definit
infect
calcul
believ
appropri
clinic
set
immunocompromis
patient
treatment
probabl
infect
would
justifi
studi
limit
number
patient
shortcom
studi
second
even
effort
made
standard
protocol
bal
procedur
studi
sampl
fulli
estim
dilut
factor
howev
describ
urea
method
tri
address
problem
anoth
difficulti
definit
infect
patient
made
effort
ensur
group
definit
infect
correct
howev
risk
misclassif
group
possibl
probabl
infect
infect
difficult
diagnos
patient
may
colon
bacteria
rather
infect
moreov
larg
proport
patient
clinic
suspect
infect
receiv
prior
antibiot
antifung
treatment
time
bronchoscopi
may
affect
grade
infect
present
misclassif
would
like
bia
estim
toward
null
prior
treatment
may
result
fals
neg
cultur
possibl
decreas
level
biomark
despit
potenti
misclassif
could
demonstr
test
biomark
especi
hbp
increas
infect
infect
reject
common
complic
lung
transplant
recipi
earli
diagnosi
treatment
import
outcom
studi
show
hbp
could
use
biomark
detect
pulmonari
infect
lntx
patient
hbp
previous
evalu
lntx
patient
could
simpl
rapid
tool
diagnosi
infect
interest
biomark
also
seem
discrimin
infect
reject
howev
relev
character
actual
marker
need
valid
larger
prospect
studi
author
manuscript
conflict
interest
disclos
describ
american
journal
transplant
one
author
bc
manuscript
list
patent
use
hbp
diagnost
tool
sepsi
file
hansa
medic
ab
author
conflict
interest
disclos
